Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: Michael G. Potter who wrote (1885)	7/16/1999 9:14:00 AM
From: Bosco	Read Replies (1) \| Respond to of 2028

hi Michael - thx for the reply, but you miss my question. I understand the hedging mechanics of a takeover [or takeunder like LU buying SPCT!] but that is not what I am asking. BTGC has been growing internally for quite some times now and it has not been in the M&A game. In fact, if anything, BTGC itself can be a prime target [for its portfolio, cash generation potentials - or even a cheap way to settle ligitation <G>.] It is doubtful Dr Fass willing to let the company go though. But I digress. Back to the original point, I am curious of your musing that BTGC is interested in acquisition. Incidentally, while it has $, considering it is a small biotech firm, but certainly not enough to do a cash deal for anything of blockbusting potentials. BTGC stock has been in part dragged down by the warrant situation, not sure if mgt wanted to commit harikari [sp?] by doing debt deal to finance an acquisition. With all these negatives [in my eyes anyway,] I wonder if you know something going on - that's why I ask Thanks again best, Bosco